169 related articles for article (PubMed ID: 29661026)
1. Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes.
Matza LS; Boye KS; Currie BM; Paczkowski R; Lando LF; Mody R; Jordan J
Curr Med Res Opin; 2018 Aug; 34(8):1457-1464. PubMed ID: 29661026
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: comparisons with liraglutide, insulin glargine, and placebo in two randomized studies.
Suzuki S; Oura T; Takeuchi M; Boye KS
Health Qual Life Outcomes; 2017 Jun; 15(1):123. PubMed ID: 28606095
[TBL] [Abstract][Full Text] [Related]
3. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy.
Boye KS; Matza LS; Stewart KD; Jordan J; Biricolti G; Del Santo S; Perez-Nieves M; Federici MO; Gentilella R; Losi S; Norrbacka K
J Med Econ; 2019 Aug; 22(8):806-813. PubMed ID: 31010349
[No Abstract] [Full Text] [Related]
4. Comparative usability study of the dulaglutide single-use pen versus the insulin degludec FlexTouch
Asakura T; Suzuki S; Aranishi T; Cai Z
Curr Med Res Opin; 2018 Jun; 34(6):1117-1124. PubMed ID: 29504812
[TBL] [Abstract][Full Text] [Related]
5. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study.
Miyagawa J; Odawara M; Takamura T; Iwamoto N; Takita Y; Imaoka T
Diabetes Obes Metab; 2015 Oct; 17(10):974-83. PubMed ID: 26179187
[TBL] [Abstract][Full Text] [Related]
6. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.
Odawara M; Miyagawa J; Iwamoto N; Takita Y; Imaoka T; Takamura T
Diabetes Obes Metab; 2016 Mar; 18(3):249-57. PubMed ID: 26661514
[TBL] [Abstract][Full Text] [Related]
7. Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.
Matfin G; Van Brunt K; Zimmermann AG; Threlkeld R; Ignaut DA
J Diabetes Sci Technol; 2015 Apr; 9(5):1071-9. PubMed ID: 25901022
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).
Yu M; Brunt KV; Milicevic Z; Varnado O; Boye KS
Clin Ther; 2017 Nov; 39(11):2284-2295. PubMed ID: 29110972
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Dulaglutide Compared with Liraglutide and Glargine in Type 2 Diabetes Mellitus Patients in Colombia.
Lasalvia P; Baquero L; Otálora-Esteban M; Castañeda-Cardona C; Rosselli D
Value Health Reg Issues; 2017 Dec; 14():35-40. PubMed ID: 29254540
[TBL] [Abstract][Full Text] [Related]
10. Network meta-analysis accurately predicted the outcome of a subsequent randomised trial comparing once weekly dulaglutide 1.5 mg and once daily liraglutide 1.8 mg.
Fahrbach JL; Fu H; Shurzinske L; Skrivanek Z; Martin S
Int J Clin Pract; 2016 Mar; 70(3):218-21. PubMed ID: 26916354
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.
Yu M; Van Brunt K; Varnado OJ; Boye KS
Diabetes Obes Metab; 2016 Apr; 18(4):419-24. PubMed ID: 26691396
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials.
Emoto M; Oura T; Matsui A; Kazama H; Iwamoto N
Endocr J; 2017 Feb; 64(2):191-206. PubMed ID: 27853058
[TBL] [Abstract][Full Text] [Related]
13. ACP Journal Club: in metformin-treated type 2 diabetes mellitus, weekly dulaglutide was noninferior to daily liraglutide for HbA1c levels.
Morey-Vargas OL; Shah P
Ann Intern Med; 2014 Nov; 161(10):JC9. PubMed ID: 25402542
[No Abstract] [Full Text] [Related]
14. Dulaglutide for the treatment of type 2 diabetes.
Scheen AJ
Expert Opin Biol Ther; 2017 Apr; 17(4):485-496. PubMed ID: 28274140
[TBL] [Abstract][Full Text] [Related]
15. Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER).
Matza LS; Boye KS; Stewart KD; Coyne KS; Wullenweber PK; Cutts KN; Jordan JB; Wang Q; Yu M; Currie BM; Malley KG; Ishak KJ; Hietpas RT; García-Pérez LE
Diabetes Obes Metab; 2020 Mar; 22(3):355-364. PubMed ID: 31646727
[TBL] [Abstract][Full Text] [Related]
16. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
[TBL] [Abstract][Full Text] [Related]
17. Dulaglutide: A Review in Type 2 Diabetes.
Burness CB; Scott LJ
BioDrugs; 2015 Dec; 29(6):407-18. PubMed ID: 26423061
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
Wysham C; Blevins T; Arakaki R; Colon G; Garcia P; Atisso C; Kuhstoss D; Lakshmanan M
Diabetes Care; 2014 Aug; 37(8):2159-67. PubMed ID: 24879836
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.
Morieri ML; Rigato M; Frison V; Simioni N; D'Ambrosio M; Tadiotto F; Paccagnella A; Lapolla A; Avogaro A; Fadini GP
Metabolism; 2020 May; 106():154190. PubMed ID: 32109448
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
